Meets or exceeds all third quarter guidance metrics GAAP Net income of $5.2 million reflects $35 million year-over-year improvement GAAP EPS of $0.11, up $0.86 versus prior-year period Adjusted EPS of $0.39, up sharply versus $0.02 in 3Q24 Operating expenses reduced 11% year-over-year, supporting continued margin expansion SAN CARLOS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Oportun Financial Corporation (Nasdaq: OPRT) (“Oportun”, or the "Company") today reported financial results for the third quarter e ...

Over 3 million Paid Subscribers, up 6% over Q3 2024 Q3 2025 revenue of $170.4 million, up 2% compared to Q3 2024 Net income of $20.5 million, up 79% compared to Q3 2024 Recurring semi-annual dividend of $0.10 per share to be paid in January 2026 SOUTH JORDAN, Utah, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cricut, Inc. (“Cricut”) (NASDAQ: CRCT), the creative technology company that has brought a connected platform for making to millions of users worldwide, today announced financial results for its third quarter en ...

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, “we,” “us,” “our,” “CGBD” or the “Company”) (NASDAQ: CGBD) today announced its financial results for its third quarter ended September 30, 2025. Justin Plouffe, CGBD’s Chief Executive Officer, said, “We continue to be active in the current market with disciplined underwriting standards. We experienced another quarter of net growth in the portfolio as we maintain leverage at the mid-point o ...

Third quarter total revenue of $160 million, Crysvita® revenue of $112 million and Dojolvi® revenue of $24 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million Bolstered balance sheet with $400 million proceeds from sale of portion of Crysvita royalty interest NOVATO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceu ...

MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Stifel 2025 Healthcare Conference and the Piper Sandler 37th Annual Healthcare Conference, both in New York, NY. Sight Sciences’ management is scheduled to present at the S ...

合作核心内容 - Arteris公司宣布Altera已获得其广泛产品组合的授权，用于开发下一代FPGA和SoC FPGA解决方案 [1] - 此次合作旨在利用Arteris的IP和软件产品来简化设计工作流程、优化数据移动，并赋能数据中心、通信、视觉、工业自动化、机器人、航空航天和国防应用中的智能计算 [1] 技术细节与应用 - Altera将部署Arteris的Ncore缓存一致性互连IP、FlexGen智能片上网络IP、用于设计集成自动化的Magillem Connectivity以及用于硬件软件集成的Magillem Registers [2] - 该技术组合将帮助Altera高效简化组装、优化片上数据移动，并加速下一代可编程架构的开发，以满足各种终端市场的动态需求 [2] - Ncore缓存一致性NoC IP、FlexGen智能NoC IP和Magillem软件的结合为开发先进半导体提供了强大基础，可优化数据移动效率、实现系统级自动化并满足一致性数据处理需求，从而提升性能并缩短上市时间 [3] 合作方评价与意义 - Altera方面表示，Arteris技术对于更快地将创新可编程解决方案推向市场至关重要，其经过硅验证的IP和软件使设计和集成更简单、更快速、风险更低 [3] - Arteris方面认为，Altera的信任证明了高性能互连IP和设计自动化软件对于推动先进设计、实现快速创新的重要性日益增长 [3] 公司背景 - Arteris是系统IP领域的全球领导者，其片上网络互连IP和片上系统集成自动化软件被全球顶级半导体和科技公司用于提升整体性能、工程生产率、降低风险与成本，并更快地将复杂设计推向市场 [4]

SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 & Recent Highlights Reported total revenue of $22.6 million in the third quarter of 2025, a 31% increase compared to the same period in 2024Achieved gross margin of 88% compared to 87% for ...

公司近期活动 - 公司将参加三场投资者会议 包括Stifel 2025 Healthcare Conference的炉边谈话（2025年11月13日 下午1:20 ET） Jeffries Global Healthcare Conference的演讲（2025年11月18日 中午12:00 ET）以及Piper 37 Annual Healthcare Conference的炉边谈话（2025年12月4日 上午9:30 ET）[1] - 相关讨论的音频网络直播将在公司投资者关系网站提供 并提供90天的回放[1] 公司业务概览 - 公司成立于2006年 专注于儿科骨科领域的发展[2] - 公司拥有超过80种产品 服务于儿科骨科市场中最大的三个类别 包括创伤与畸形、脊柱侧弯以及运动医学/其他手术[2] - 公司全球销售组织专注于儿科骨科 产品在美国及全球超过70个国家分销[2]

- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday, November 12, 2025, at 4:30 pm ET - NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that the company will report third quarter 2025 financial results and trial investigators will provide ...

MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, today announced results for its third quarter ended September 30, 2025. Third Quarter 2025 Summary Net Sales Decreased 1.7%Comparable Store Sales Decreased 1.4% Gross Margin of 62.9%Net Loss of $1.6 Million and Adjusted EBITDA of $2.0 MillionNo Debt Outstanding and $24.1 million of Cash at Quarter-End Management Commentary – Cabell Lo ...